Symbols / NERV
NERV Chart
About
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of negative symptoms in patients with schizophrenia. The company also has exclusive rights to develop and commercialize MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 270.46M |
| Enterprise Value | 91.42M | Income | -14.03M | Sales | — |
| Book/sh | -4.95 | Cash/sh | 1.76 | Dividend Yield | — |
| Payout | 0.00% | Employees | 8 | IPO | — |
| P/E | — | Forward P/E | -11.57 | PEG | — |
| P/S | — | P/B | -1.26 | P/C | — |
| EV/EBITDA | -6.25 | EV/Sales | — | Quick Ratio | 4.60 |
| Current Ratio | 4.87 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -1.85 | EPS next Y | -0.54 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-05 07:00 | ROA | -25.82% |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 43.27M |
| Shs Float | 3.98M | Short Float | 0.99% | Short Ratio | 5.53 |
| Short Interest | — | 52W High | 12.46 | 52W Low | 1.15 |
| Beta | -0.23 | Avg Volume | 73.31K | Volume | 113.75K |
| Target Price | $4.50 | Recom | None | Prev Close | $6.32 |
| Price | $6.25 | Change | -1.11% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$4.50
Mean price target
2. Current target
$6.25
Latest analyst target
3. DCF / Fair value
$-3.81
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$6.25
Low
$4.00
High
$5.00
Mean
$4.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-06 | main | HC Wainwright & Co. | Neutral → Neutral | $4 |
| 2025-02-26 | reit | HC Wainwright & Co. | Neutral → Neutral | $5 |
| 2024-11-06 | reit | HC Wainwright & Co. | Neutral → Neutral | $5 |
| 2024-08-07 | main | HC Wainwright & Co. | Neutral → Neutral | $5 |
| 2024-05-02 | main | HC Wainwright & Co. | Neutral → Neutral | $7 |
| 2024-02-27 | reit | HC Wainwright & Co. | Neutral → Neutral | $11 |
| 2023-08-02 | main | HC Wainwright & Co. | Neutral → Neutral | $11 |
| 2023-05-16 | reit | HC Wainwright & Co. | Neutral → Neutral | $8 |
| 2023-05-02 | reit | HC Wainwright & Co. | — → Neutral | $8 |
| 2023-03-09 | reit | HC Wainwright & Co. | — → Neutral | $8 |
| 2022-11-10 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2022-10-17 | down | JMP Securities | Market Outperform → Market Perform | — |
- Minerva Neurosciences (NASDAQ: NERV) secures up to $200M for roluperidone Phase 3 - Stock Titan ue, 21 Oct 2025 07
- Minerva Neurosciences Stock (NERV) Opinions on $200M Funding Deal | NERV Stock News - Quiver Quantitative ue, 21 Oct 2025 07
- Institutions profited after Minerva Neurosciences, Inc.'s (NASDAQ:NERV) market cap rose US$27m last week but individual investors profited the most - Yahoo Finance Mon, 16 Feb 2026 08
- Minerva Neurosciences stock soars after securing $200 million financing - Investing.com ue, 21 Oct 2025 07
- Minerva Neurosciences, Inc.'s (NASDAQ:NERV) market cap touched US$271m last week, benefiting both retail investors who own 55% as well as institutions - Sahm Mon, 16 Feb 2026 08
- Why Is Minerva Neurosciences Stock (NERV) Up 165% Today? - TipRanks ue, 21 Oct 2025 07
- Minerva Neurosciences Inc (NERV) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade ue, 21 Oct 2025 14
- Minerva Neurosciences Jumps 339% On $200M Financing Agreement - Nasdaq ue, 21 Oct 2025 07
- Minerva Neurosciences Stock Hits Near 2-Year High On FDA Pathway, $200M Boost — Retail Sees FDA Catalyst - Stocktwits Wed, 22 Oct 2025 07
- Minerva jumps on phase III funding, leading neuro stocks - BioWorld MedTech hu, 04 Dec 2025 08
- Minerva to spotlight potential first drug for key schizophrenia symptoms - Stock Titan Mon, 26 Jan 2026 08
- Minerva Neurosciences Appoints Dr. Inderjit Kaul to Board of Directors as Company Advances Clinical Development of Roluperidone for Schizophrenia Treatment - Quiver Quantitative Wed, 19 Nov 2025 08
- Minerva Neurosciences Secures $200M for Drug Trials - TipRanks Wed, 22 Oct 2025 07
- Minerva Neurosciences’ Unexpected Surge: Should You Invest? - StocksToTrade ue, 21 Oct 2025 07
- NERV Stock Price, News & Analysis - Stock Titan Fri, 25 Apr 2025 00
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | -569.92 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.03 |
| NormalizedEBITDA | 4.75M | -23.09M | -25.22M | -45.26M |
| TotalUnusualItems | 1.27M | 1.40M | 529.21K | -16.33K |
| TotalUnusualItemsExcludingGoodwill | 1.27M | 1.40M | 529.21K | -16.33K |
| NetIncomeFromContinuingOperationNetMinorityInterest | 1.44M | -30.01M | -32.11M | -49.91M |
| ReconciledDepreciation | 22.47K | 30.98K | 8.51K | 101.79K |
| EBITDA | 6.02M | -21.69M | -24.69M | -45.28M |
| EBIT | 6.00M | -21.72M | -24.70M | -45.38M |
| NetInterestIncome | -4.56M | -8.28M | -7.41M | -6.33M |
| InterestExpense | 4.56M | 8.28M | 7.41M | 6.33M |
| InterestIncome | 1.44M | 556.95K | 16.52K | |
| NormalizedIncome | 168.44K | -31.40M | -32.64M | -49.89M |
| NetIncomeFromContinuingAndDiscontinuedOperation | 1.44M | -30.01M | -32.11M | -49.91M |
| TotalExpenses | 21.85M | 23.12M | 25.23M | 45.37M |
| TotalOperatingIncomeAsReported | -21.85M | -23.12M | -25.23M | -45.37M |
| DilutedAverageShares | 7.57M | 6.51M | 5.34M | 5.34M |
| BasicAverageShares | 7.57M | 6.51M | 5.34M | 5.34M |
| DilutedEPS | 0.19 | -4.61 | -6.01 | -9.35 |
| BasicEPS | 0.19 | -4.61 | -6.01 | -9.35 |
| DilutedNIAvailtoComStockholders | 1.44M | -30.01M | -32.11M | -49.91M |
| NetIncomeCommonStockholders | 1.44M | -30.01M | -32.11M | -49.91M |
| NetIncome | 1.44M | -30.01M | -32.11M | -49.91M |
| NetIncomeIncludingNoncontrollingInterests | 1.44M | -30.01M | -32.11M | -49.91M |
| NetIncomeContinuousOperations | 1.44M | -30.01M | -32.11M | -49.91M |
| TaxProvision | 0.00 | -1.80M | ||
| PretaxIncome | 1.44M | -30.01M | -32.11M | -51.71M |
| OtherIncomeExpense | 27.85M | 1.40M | 529.21K | -16.33K |
| OtherNonOperatingIncomeExpenses | 26.58M | |||
| GainOnSaleOfSecurity | 1.27M | 1.40M | 529.21K | -16.33K |
| NetNonOperatingInterestIncomeExpense | -4.56M | -8.28M | -7.41M | -6.33M |
| InterestExpenseNonOperating | 4.56M | 8.28M | 7.41M | 6.33M |
| InterestIncomeNonOperating | 1.44M | 556.95K | 16.52K | |
| OperatingIncome | -21.85M | -23.12M | -25.23M | -45.37M |
| OperatingExpense | 21.85M | 23.12M | 25.23M | 45.37M |
| ResearchAndDevelopment | 11.90M | 12.71M | 14.65M | 32.04M |
| SellingGeneralAndAdministration | 9.95M | 10.41M | 10.58M | 13.33M |
| GeneralAndAdministrativeExpense | 9.95M | 10.41M | 10.58M | 13.33M |
| OtherGandA | 9.95M | 10.41M | 10.58M | 13.33M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 6.99M | 6.99M | 5.34M | 5.34M |
| ShareIssued | 6.99M | 6.99M | 5.34M | 5.34M |
| TotalDebt | 0.00 | |||
| TangibleBookValue | -40.56M | -43.34M | -34.94M | -6.94M |
| InvestedCapital | -25.69M | -28.46M | -20.02M | 7.98M |
| WorkingCapital | 19.43M | 38.66M | 38.78M | 59.38M |
| NetTangibleAssets | -40.56M | -43.34M | -34.94M | -6.94M |
| CapitalLeaseObligations | 0.00 | |||
| CommonStockEquity | -25.69M | -28.46M | -20.02M | 7.98M |
| TotalCapitalization | -25.69M | -28.46M | -20.02M | 7.98M |
| TotalEquityGrossMinorityInterest | -25.69M | -28.46M | -20.02M | 7.98M |
| StockholdersEquity | -25.69M | -28.46M | -20.02M | 7.98M |
| RetainedEarnings | -395.38M | -396.82M | -366.81M | -334.70M |
| AdditionalPaidInCapital | 369.68M | 368.36M | 346.79M | 342.68M |
| CapitalStock | 699.00 | 699.00 | 534.00 | 534.00 |
| CommonStock | 699.00 | 699.00 | 534.00 | 534.00 |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 62.84M | 85.36M | 75.11M | 69.15M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 60.00M | 82.02M | 73.73M | 66.33M |
| OtherNonCurrentLiabilities | 60.00M | 82.02M | 73.73M | 66.33M |
| NonCurrentDeferredLiabilities | 0.00 | |||
| NonCurrentDeferredTaxesLiabilities | 0.00 | |||
| CurrentLiabilities | 2.84M | 3.34M | 1.38M | 2.82M |
| CurrentCapitalLeaseObligation | 0.00 | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 363.18K | 590.77K | 14.83K | 0.00 |
| PayablesAndAccruedExpenses | 2.47M | 2.75M | 1.36M | 2.82M |
| CurrentAccruedExpenses | 865.82K | 944.33K | 393.08K | 965.74K |
| Payables | 1.61M | 1.81M | 969.67K | 1.85M |
| AccountsPayable | 1.61M | 1.81M | 969.67K | 1.85M |
| TotalAssets | 37.14M | 56.90M | 55.09M | 77.12M |
| TotalNonCurrentAssets | 14.87M | 14.90M | 14.93M | 14.92M |
| GoodwillAndOtherIntangibleAssets | 14.87M | 14.89M | 14.91M | 14.92M |
| OtherIntangibleAssets | 17.03K | 42.57K | 51.08K | |
| Goodwill | 14.87M | 14.87M | 14.87M | 14.87M |
| NetPPE | 5.44K | 10.88K | 16.33K | 0.00 |
| GrossPPE | 16.33K | 0.00 | ||
| OtherProperties | 16.33K | |||
| BuildingsAndImprovements | 0.00 | |||
| Properties | 0.00 | |||
| CurrentAssets | 22.27M | 42.00M | 40.16M | 62.20M |
| OtherCurrentAssets | 806.89K | 989.87K | 3.97M | 1.35M |
| RestrictedCash | 100.00K | 100.00K | 100.00K | 100.00K |
| PrepaidAssets | 1.35M | |||
| CashCashEquivalentsAndShortTermInvestments | 21.36M | 40.91M | 36.09M | 60.76M |
| CashAndCashEquivalents | 21.36M | 40.91M | 36.09M | 60.76M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -19.55M | -14.78M | -24.66M | -24.60M |
| IssuanceOfCapitalStock | 0.00 | 20.00M | 0.00 | 0.00 |
| CapitalExpenditure | -16.33K | |||
| InterestPaidSupplementalData | 0.00 | |||
| EndCashPosition | 21.46M | 41.01M | 36.19M | 60.86M |
| BeginningCashPosition | 41.01M | 36.19M | 60.86M | 25.46M |
| ChangesInCash | -19.55M | 4.82M | -24.66M | 35.40M |
| FinancingCashFlow | 0.00 | 19.60M | -5.00 | 60.00M |
| CashFlowFromContinuingFinancingActivities | 0.00 | 19.60M | -5.00 | 60.00M |
| NetOtherFinancingCharges | -396.29K | -5.00 | 60.00M | |
| ProceedsFromStockOptionExercised | 0.00 | |||
| NetCommonStockIssuance | 0.00 | 20.00M | 0.00 | 0.00 |
| CommonStockIssuance | 0.00 | 20.00M | 0.00 | 0.00 |
| InvestingCashFlow | 0.00 | 0.00 | -16.33K | 0.00 |
| CashFlowFromContinuingInvestingActivities | 0.00 | -16.33K | 0.00 | |
| NetInvestmentPurchaseAndSale | 0.00 | |||
| SaleOfInvestment | 0.00 | |||
| PurchaseOfInvestment | 0.00 | |||
| NetPPEPurchaseAndSale | 0.00 | -16.33K | 0.00 | |
| PurchaseOfPPE | 0.00 | -16.33K | 0.00 | |
| OperatingCashFlow | -19.55M | -14.78M | -24.65M | -24.60M |
| CashFlowFromContinuingOperatingActivities | -19.55M | -14.78M | -24.65M | -24.60M |
| ChangeInWorkingCapital | -320.60K | 4.94M | -4.06M | 259.33K |
| ChangeInOtherWorkingCapital | -3.12M | |||
| ChangeInOtherCurrentLiabilities | 0.00 | -111.23K | ||
| ChangeInOtherCurrentAssets | 0.00 | 3.12M | -3.12M | -36.27K |
| ChangeInPayablesAndAccruedExpense | -503.57K | 1.96M | -1.44M | -230.07K |
| ChangeInAccruedExpense | -306.10K | 1.13M | -557.83K | -1.09M |
| ChangeInPayable | -197.48K | 835.65K | -883.55K | 857.60K |
| ChangeInAccountPayable | -197.48K | 835.65K | -883.55K | 857.60K |
| ChangeInPrepaidAssets | 182.97K | -141.75K | 498.24K | 636.90K |
| OtherNonCashItems | -22.02M | 8.28M | 7.41M | 6.33M |
| StockBasedCompensation | 1.33M | 1.97M | 4.11M | 5.22M |
| AssetImpairmentCharge | 0.00 | 15.20M | ||
| AmortizationOfSecurities | 0.00 | |||
| DeferredTax | -1.80M | |||
| DeferredIncomeTax | -1.80M | |||
| DepreciationAmortizationDepletion | 22.47K | 30.98K | 8.51K | 101.79K |
| DepreciationAndAmortization | 22.47K | 30.98K | 8.51K | 101.79K |
| AmortizationCashFlow | 17.03K | 25.54K | 8.51K | 0.00 |
| AmortizationOfIntangibles | 17.03K | 25.54K | 8.51K | 0.00 |
| Depreciation | 5.44K | 5.44K | 0.00 | 101.79K |
| NetIncomeFromContinuingOperations | 1.44M | -30.01M | -32.11M | -49.91M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for NERV
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|